Platinum, Palladium...
Health Care: Drugs
Cellceutix Corporation (CTIX: OTC)
$1.85 0.06 | 3.35%
06/19/13 - 03:56 PM ET
Company Income Statement
| Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | |
| Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General, and Administrative Expenses | 3.56M | 4.38M | 1.35M | 1.04M |
| Research & Development | 632.80K | 1.34M | 2.00M | 391.00K |
| Operating Income before D & A (EBITDA) | -4.20M | -5.72M | -3.35M | -1.43M |
| Depreciation & Amortization | 60.27K | 25.63K | 22.70K | 0.00 |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Income - Net | -439.89K | 0.00 | 0.00 | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | -17.90K | -19.00K |
| Total Income Before Interest Expenses (EBIT) | -4.70M | -5.75M | -3.39M | -1.45M |
| Interest Expense | 257.41K | 215.92K | 69.34K | 34.00K |
| Pre-Tax Income | -4.95M | -5.96M | -3.46M | -1.48M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -4.89M | -5.94M | -3.43M | -1.48M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -4.89M | -5.94M | -3.43M | -1.48M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -4.89M | -5.94M | -3.43M | -1.48M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-4.89M | -5.94M | -3.42M | -1.47M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -4.96M | -5.94M | -3.43M | -1.48M |
| Basic EPS from Continuing Ops. | -0.06 | -0.06 | -0.04 | -0.02 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.06 | -0.06 | -0.04 | -0.02 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.06 | -0.06 | -0.04 | -0.02 |
| Basic Normalized Net Income/Share | -0.06 | -0.06 | -0.04 | -0.02 |
| EPS fr Continuing Ops. | -0.06 | -0.06 | -0.04 | -0.02 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.06 | -0.06 | -0.04 | -0.02 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.06 | -0.06 | -0.04 | -0.02 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.06 | -0.06 | -0.04 | -0.02 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with CTIX
- Portfolio NameUser Type
Latest CTIX Headlines from TheStreet
- Seeking Alpha Author Used Multiple Aliases to Tout Biotech Stocks 01.28.13 | 06:01 am
- Cheap Tickets Up as Cendant Extends Share Offer Deadline 09.24.01 | 08:09 am
- Cheap Tickets Tumbles on Warning 06.26.01 | 11:06 am
- The Daily Interview: Online Travel Skies Getting Crowded 06.13.01 | 10:06 am
- Ticker-Tape Parade: Cendant Buys Cheap Tickets, Semis Get an Upgrade 12.31.69 | 07:12 pm
- Cheap Tickets Leaps on Offer From Cendant 12.31.69 | 07:12 pm
Press Releases for CTIX
- Top Stocks On The Move: Petrosonic Energy Inc., Truli Media Group Inc., Cellceutix Corp., And OBJ Enterprises Inc. - PR Newswire 01.07.13 | 09:01 am
- Fiscal Cliff Stock Reports: Amarantus Biosciences, Cellceutix Corporation, World Moto, Facebook, Ford Motor Company - PR Newswire 12.27.12 | 08:12 am
- Cellceutix CEO, Leo Ehrlich, Conducts Interview With "Biotech Stock Trader"; Dr. Paul Ginsberg, (Renowned Patent Attorney) Joins Cellceutix Advisory Board - PR Newswire 04.18.11 | 07:04 am
- Cellceutix Poster Presentation On Its P53 Cancer Breakthrough Attracts Wide Interest At 102nd AACR Meeting - PR Newswire 04.11.11 | 06:04 am
- Cellceutix Cancer Drug, Kevetrinâ¢, Shows Increased Levels Of P21; Biomarker For Cancer Trials - PR Newswire 03.31.11 | 08:03 am
- Cellceutix Announces That It Has Signed Confidential Disclosure Agreement For Its Autism Drug With Large Pharmaceutical Company - PR Newswire 03.28.11 | 07:03 am
- Cellceutix Anti-Cancer Breakthrough Selected For Poster Presentation At American Association For Cancer Research (AACR) - PR Newswire 03.21.11 | 07:03 am
- Cellceutix Reports Production Of Its Anti-Cancer Drug Kevetrin⢠Has Begun - PR Newswire 03.14.11 | 06:03 am
- Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company - PR Newswire 03.08.11 | 04:03 pm
- Cellceutix Discovers Drug Activates 'Guardian Angel P53' In Fight Against Leukemia - PR Newswire 03.07.11 | 07:03 am
Partner Headlines for CTIX
